Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00751231 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
A Phase 2 study, sponsored by Portola Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 652
- Enrollment target
NCT00751231 is a Phase 2 study that has completed, run by Portola Pharmaceuticals. The registered enrollment target is 652 participants.
The verdict
NCT00751231, a Phase 2 study, has completed, sponsored by Portola Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 652 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be randomized to clopidogrel or to one of three dose levels of PRT060128.
Interventions
- DRUG clopidogrel
- DRUG PRT060128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 652 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00751231
The ClinicalTrials.gov registry entry for NCT00751231 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 652 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Portola Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clopidogrel is the first listed.
NCT00751231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00751231 about?
NCT00751231 is a clinical study titled "A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI". This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be randomized to clopidog...
What is the current status of trial NCT00751231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 652 participants. The study started on 2008-12. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00751231?
The interventions under investigation include: clopidogrel (DRUG), PRT060128 (DRUG).
Who is sponsoring clinical trial NCT00751231?
This trial is sponsored by Portola Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.